COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

Short Title: COVID-19 Post-hospital Thrombosis Prevention Study

A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge

ClinicalTrials.gov Number:

Sponsors:
National Institute of Neurological Disorders (NINDS), National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA), Operation Warp Speed (OWS), and the U.S. Department of Health & Human Services (HHS)

Version Number: 2.1

29 October 2020
## Protocol Development Committee Leadership

### Study Chair:
Thomas L. Ortel, MD, PhD  
Professor of Medicine and Pathology  
Chief, Division of Hematology  
Duke University Medical Center  
Durham, NC 27710  
Tel. 919-681-6049  
Fax. 919-681-6160  
E-mail: thomas.ortel@duke.edu

### Study Co-Chair:
Alison Morris, MD, MS  
Professor of Medicine, Immunology, and Clinical and Translational Research  
Division Chief, Pulmonary, Allergy and Critical Care Medicine  
Director, Center for Medicine and the Microbiome  
Vice Chair for Clinical Research, Department of Medicine  
UPMC Chair in Translational Pulmonary and Critical Care Medicine  
E-mail: morrisa@upmc.edu

### Principal Investigator:
Tracy Yu-Ping Wang, MD  
Associate Professor of Medicine  
Duke Clinical Research Institute Member  
Duke University Medical Center  
Durham, NC 27710  
Tel. 919-668-8907  
E-mail: tracy.wang@duke.edu

### Study Biostatisticians:
Abdus S. Wahed, PhD  
Professor of Biostatistics  
University of Pittsburgh, Graduate School of Public Health  
Pittsburgh, PA  
E-mail: WahedA@edc.pitt.edu

Kevin J. Anstrom, PhD  
Professor of Biostatistics and Bioinformatics  
Duke University Medical Center  
Durham, NC 27710  
Tel. 919-668-8902  
E-mail: kevin.anstrom@duke.edu

Eric Leifer, PhD  
NHLBI  
leifer@nhlbi.nih.gov

### Research Communication Center:
Jerry A. Krishnan, MD, PhD  
Professor of Medicine and Public Health  
Associate Vice Chancellor for Population Health Sciences  
University of Illinois at Chicago  
1220 S. Wood Street, 3rd Floor  
Chicago, IL 60608  
Tel 312-413-0637  
E-mail: jakris@uic.edu
| NHLBI Representative: | Andrei Kindzelski, MD, PhD  
kindzelski@nhlbi.nih.gov |
|-----------------------|--------------------------|
| HHS Representative:   | David Douglas  
David.Douglas@hhs.gov |
| IND                   | Pending                  |
| ClinicalTrials.gov Identifier |                   |
Statement of Compliance

This study will be conducted in accordance with the Code of Federal Regulations on the Protection of Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable US government research regulations, and institutional research policies and procedures. The International Conference on Harmonization (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to as “ICH-GCP” or “E6”) will be applied only to the extent that it is compatible with FDA and DHHS regulations. The Principal Investigator will assure that no deviation from, or changes to, the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.

The signature below provides the necessary assurance that this study will be conducted according to all stipulations of the protocol including statements regarding confidentiality, and according to local legal and regulatory requirements, US federal regulations, and ICH E6(R2) GCP guidelines.

Site Investigator Signature:

Signed: ___________________________ Date: _____________
Name and Title
Table of Contents

STATEMENT OF COMPLIANCE .......................................................................................................... IV
MASTER PROTOCOL SUMMARY ...................................................................................................... 8
1. INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE .... 11
   1.1 BACKGROUND INFORMATION, SIGNIFICANCE AND RELEVANT LITERATURE .......... 11
       1.1.1 Thromboprophylactic therapy: rationale, potential benefits, and potential risks .... 13
2. STUDY DESIGN .......................................................................................................................... 14
   2.1 OVERALL STUDY DESIGN .............................................................................................. 14
   2.2 RANDOMIZATION ............................................................................................................. 14
   2.3 STUDY INTERVENTIONS .................................................................................................. 15
   2.4 BIOREPOSITORY .............................................................................................................. 15
3. OBJECTIVES AND PURPOSE ................................................................................................. 15
4. STUDY DESIGN AND ENDPOINTS ...................................................................................... 16
   4.1 DESCRIPTION OF STUDY DESIGN: STAGE 1 ................................................................. 17
   4.2 STUDY ENDPOINTS FOR STAGE I ............................................................................... 18
       4.2.1 Primary Study Endpoints ..................................................................................... 18
       4.2.2 Key Secondary and Exploratory Endpoints .......................................................... 18
       4.2.3 Safety Endpoints for Stage 1 .............................................................................. 18
       4.2.4 Adjudication of outcome events ......................................................................... 18
5. STUDY ENROLLMENT ............................................................................................................. 19
   5.1 INCLUSION CRITERIA ....................................................................................................... 19
   5.2 EXCLUSION CRITERIA ..................................................................................................... 19
   5.3 VULNERABLE SUBJECTS ............................................................................................... 19
   5.4 STRATEGIES FOR RECRUITMENT AND RETENTION ..................................................... 19
   5.5 DURATION OF STUDY PARTICIPATION ......................................................................... 20
   5.6 PARTICIPANT WITHDRAWAL OR TERMINATION ........................................................... 21
       5.6.1 Reasons for Withdrawal or Termination ............................................................... 21
       5.6.2 Premature Termination or Suspension of Study ................................................... 21
   5.7 STUDY AGENTS .............................................................................................................. 21
   5.8 DURATION OF THERAPY .................................................................................................. 21
6. STUDY PROCEDURES AND SCHEDULE ............................................................................. 22
   6.1 STUDY SCHEDULE ......................................................................................................... 22
   6.2 LABORATORY PROCEDURES/EVALUATIONS ................................................................. 22
       6.2.1 Study encounters .................................................................................................... 22
   6.3 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES ......................... 23
   6.4 EXPEDITED CRITICAL AND MAJOR EVENT REPORTING ........................................... 24
   6.5 DATA AND SAFETY MONITORING PLAN AND STUDY HALTING RULES .................. 24
7. STATISTICAL CONSIDERATIONS ......................................................................................... 24
   7.1 STATISTICAL AND ANALYTICAL PLANS (SAP) ............................................................ 24
   7.2 POWER AND SAMPLE SIZE CALCULATIONS ............................................................... 24
   7.3 PRIMARY OUTCOME ANALYSIS .................................................................................... 25
7.4 TABULATION OF INDIVIDUAL RESPONSE DATA ............................................................. 25
7.5 SUB-GROUP ANALYSES ............................................................................................ 25
    7.5.1 Safety Analyses ............................................................................................... 26
    7.5.2 Adherence and Retention Analyses ............................................................... 26
    7.5.3 Baseline Descriptive Statistics .................................................................... 26
    7.5.4 Planned Interim Analysis, Futility, and Efficacy ............................................ 26
    7.5.5 Safety Review ............................................................................................... 27
    7.5.6 Subgroup Analyses based on Anti-Platelet Use, WHO Severity Score, and Other
    Pre-specified Characteristics .............................................................................. 27
7.5.7 Analyses of Duration of Treatment ................................................................. 27

8. MEASURES TO MINIMIZE BIAS ............................................................................... 28
8.1 ENROLLMENT/RANDOMIZATION .......................................................................... 28

9. SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS ............. 28

10. QUALITY ASSURANCE AND QUALITY CONTROL .............................................. 28

11. ETHICS/PROTECTION OF HUMAN SUBJECTS.................................................... 28
    11.1 ETHICAL STANDARD ........................................................................................ 28
    11.2 INSTITUTIONAL REVIEW BOARD .................................................................... 28
    11.3 INFORMED CONSENT PROCESS ................................................................... 29
        11.3.1 Consent/Assent and Other Informational Documents Provided to Participants ...29
        11.3.2 Consent Procedures and Documentation .................................................. 29
    11.4 POSTING OF CLINICAL TRIAL CONSENT FORM ......................................... 29
    11.5 PARTICIPANT AND DATA CONFIDENTIALITY .............................................. 29

12. DATA HANDLING AND RECORD KEEPING .......................................................... 30
    12.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES ...................... 30
    12.2 STUDY RECORDS RETENTION ....................................................................... 31
    12.3 PROTOCOL DEVIATIONS .............................................................................. 31
    12.4 PUBLICATION AND DATA SHARING POLICY ............................................. 31

13. STUDY FINANCES .................................................................................................. 32
    13.1 FUNDING SOURCE .......................................................................................... 32
    13.2 COSTS TO THE PARTICIPANT ....................................................................... 32

14. CONFLICT OF INTEREST POLICY ........................................................................ 32

15. REFERENCES ......................................................................................................... 32

APPENDIX 1: CRITERIA FOR ADDITION AND REPLACEMENT OF ARMS ..................... 35

APPENDIX 2: DEFINITION AND DETERMINATION OF OUTCOMES .............................. 36
    A2.1 APPROACH TO ASCERTAINMENT AND VERIFICATION OF OUTCOMES .......... 36
    A2.2 OUTCOME DEFINITIONS ............................................................................. 36

APPENDIX 3. BIOSPECIMENS .................................................................................... 38
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTIV</td>
<td>Accelerating COVID-19 Therapeutic Interventions and Vaccines</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus Disease</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CRNMB</td>
<td>Clinically Relevant non-Major Bleeding</td>
</tr>
<tr>
<td>DCC</td>
<td>Data Coordinating Center</td>
</tr>
<tr>
<td>DHHS</td>
<td>Department of Health and Human Services</td>
</tr>
<tr>
<td>DIC</td>
<td>Disseminated intravascular coagulation</td>
</tr>
<tr>
<td>DOAC</td>
<td>Direct oral anticoagulant</td>
</tr>
<tr>
<td>DSMB</td>
<td>Data and Safety Monitoring Board</td>
</tr>
<tr>
<td>DVT</td>
<td>Deep Venous Thrombosis</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>ICF</td>
<td>Informed Consent Form</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>ISTH</td>
<td>International Society on Thrombosis and Haemostasis</td>
</tr>
<tr>
<td>ITT</td>
<td>Intent to Treat</td>
</tr>
<tr>
<td>LAR</td>
<td>Legally Authorized Representative</td>
</tr>
<tr>
<td>LMWH</td>
<td>Low Molecular Weight Heparin</td>
</tr>
<tr>
<td>MOP</td>
<td>Manual of Procedures</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>PE</td>
<td>Pulmonary Embolism</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>QA</td>
<td>Quality Assurance</td>
</tr>
<tr>
<td>QC</td>
<td>Quality Control</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event/Serious Adverse Experience</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedure</td>
</tr>
<tr>
<td>VTE</td>
<td>Venous thromboembolism</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
# Master Protocol Summary

<table>
<thead>
<tr>
<th>Title</th>
<th>COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A multicenter, adaptive, prospective, randomized trial evaluating the</td>
</tr>
<tr>
<td></td>
<td>efficacy and safety of antithrombotic strategies in patients with COVID-</td>
</tr>
<tr>
<td></td>
<td>19 following hospital discharge</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Short Title</th>
<th>COVID-19 Post-hospital Thrombosis Prevention Study</th>
</tr>
</thead>
</table>

| Brief Summary | This study is an adaptive, prospective, randomized trial designed to  |
|               | compare the effectiveness and safety of antithrombotic therapy with no  |
|               | antithrombotic therapy after hospitalization for 48 hours or longer |
|               | for COVID-19. For Stage 1 of this study, participants will be          |
|               | randomized to either prophylactic anticoagulation or no anticoagulant |
|               | therapy for 30 days, and then followed for an additional 60 days after |
|               | the completion of treatment (total duration of follow-up, approximately |
|               | 90 days). Biobanking of samples for future biomarker and mechanistic  |
|               | studies will be available for centers able to participate and collect  |
|               | samples from eligible participants. Samples will be collected at the    |
|               | time of enrollment and after the completion of 30 days of therapy.     |

| Objectives | 1. Primary Objective: To determine the most effective and safe antithrombotic strategy to prevent the composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality by 30 days following discharge from the hospital. |
|            | 2. Secondary Objectives: To determine the most effective and safe antithrombotic strategy on (1) the endpoint of venous thromboembolism (inclusive of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism) by 30 days in the study population; (2) the endpoint of arterial thromboembolism (inclusive of ischemic stroke, myocardial infarction, other arterial thromboembolism) by 30 days in the study population; and (3) the composite primary outcome by 45 and 90 days following discharge from the hospital. |
|            | 3. To establish a repository of biospecimens collected at the time of enrollment and after completion of therapy. |

| Methodology | Adaptive, prospective, randomized controlled trial |
| **Endpoint** | Primary Endpoint: First occurrence of any of the components of the composite endpoint of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality by 30 days post-discharge from the hospital  
Secondary Endpoints: (1) Venous thromboembolism (inclusive of symptomatic DVT of the upper or lower extremities, symptomatic and/or clinically relevant PE, and other symptomatic venous thrombosis, including cerebral sinus and splanchnic vein thrombosis) by 30 days post-discharge from the hospital; (2) Arterial thromboembolism (inclusive of symptomatic ischemic stroke, myocardial infarction, and other symptomatic arterial thromboembolic events) by 30 days post-discharge from the hospital; and (3) the composite primary endpoint by 45 days and 90 days post-discharge from the hospital  
Primary Safety Endpoints: Major bleeding, as defined by the ISTH; clinically-relevant non-major bleeding |
| **Study Duration** | At least one year |
| **Participant Duration** | Ninety days from randomization |
| **Duration of assigned treatment strategy** | 30 days for the primary outcome in Stage 1. |
| **Population** | Adults ≥ 18 years of age with COVID-19 who are hospitalized for 48 hours or longer and who are ready for discharge from the hospital |
| **Key exclusion criteria** | 1. Clinical requirement for anticoagulant therapy (therapeutic dose or prophylactic dose)  
2. Contraindication to anticoagulant therapy  
3. Anticipated life-expectancy < 90 days |
| **Study Sites** | Up to 400 sites |
| **Number of participants** | The estimated sample size (for Stage 1) is 2,660 participants per Study Arm based on an estimated baseline rate of the primary endpoint of ~4%. |
### Description of Study Agents (Stage 1)

Stage 1 is a two-arm trial incorporating:
1. Prophylactic dose anticoagulant therapy
2. Matching placebo

Participants will be enrolled prior to discharge from the hospital, randomized as close to time of discharge as possible, and will begin the study medication (either prophylactic anticoagulation or matching placebo) upon discharge from the hospital for a total of 30 days. Study participants will be stratified based on: (1) whether or not they are taking an antiplatelet agent (e.g., aspirin, clopidogrel); and (2) on their WHO ordinal scale score dichotomized (below five vs. five or above).

Subsequent stages may investigate alternative antithrombotic strategies or focus on selected high-risk patient subsets.

### Key Procedures

See arm-specific Appendices

### Statistical Analysis

A frequentist approach has been used for the sample size calculations. Interim analyses will be used to guide decisions about stopping based on efficacy and futility. The primary analyses will be based on intention-to-treat approaches.
1. Introduction, Background Information and Scientific Rationale

1.1 Background Information, Significance and Relevant Literature

In December 2019, an outbreak of pneumonia of unknown cause was first observed in Wuhan, the capital of Hubei province in China. By early January, a novel coronavirus was isolated from these patients, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and initial descriptive clinical reports of the pandemic designated coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) began to appear shortly afterwards (1). The disease has spread explosively, and, by early July 2020, about 7 months from the initial reports, more than 11 million people worldwide had been confirmed to have a COVID-19 infection, with more than 530,000 deaths. In addition to the healthcare problems associated with this coronavirus, it has resulted in worldwide disruption of everyday life as measures have been introduced to interfere with the rapid spread of the virus and treat those patients with the infection.

The clinical manifestations associated with COVID-19 range from asymptomatic infections through severe pneumonia and death. A significant inflammatory response is frequently seen in patients who require hospitalization, associated with dramatic elevations in inflammatory biomarkers such as the ESR and CRP, as well as proinflammatory cytokines such as IL6 and others. This robust inflammatory response is also associated with elevated fibrinogen levels, as well as increased levels of D-dimers, even at initial presentation to the hospital (2). Notably, elevated D-dimer levels were associated with increased mortality (2, 3), although it was also noted that these patients were not developing hemorrhagic complications as might be seen with disseminated intravascular coagulopathy (DIC) (4, 5).

Prothrombotic manifestations of COVID-19

Subsequently, multiple reports have appeared documenting an increased incidence of venous thromboembolism (VTE) in COVID-19 positive patients, particularly those who required care in an ICU setting (6, 7). The cumulative frequency of symptomatic VTE was 25% by 21 days in one study (7), and these events occurred in some patients despite the use of VTE prophylaxis. Using surveillance ultrasound imaging, a second study reported a frequency approaching 70% of patients with severe COVID-19, but almost a quarter of these patients had superficial venous thrombosis (8). In contrast, other studies have found a lower frequency of radiographically-confirmed VTE (7.6% in critically ill patients) and bleeding rates that were not insignificant (5.6% in critically ill patients) (5). Arterial events, including ischemic stroke, MI, and peripheral arterial thromboembolism have also been reported, although they appear to occur less frequently than VTE (9, 10).

Several studies have suggested that for hospitalized patients with COVID-19, prophylactic dose anticoagulant therapy may be insufficient (6, 7). In addition, a recent retrospective cohort study reported that systemic therapeutic anticoagulation was associated with improved survival, although this study did not specifically look at patients with thromboembolic events (11). A separate, prospective randomized trial that is part of the NIH-supported ACTIV-4 program will investigate the dose of anticoagulant therapy in the inpatient population.

There are also an increasing number of reports describing patients with COVID-19 who develop thromboembolic events in the outpatient setting. Two recent studies described patients with COVID-19 being evaluated for progressive respiratory symptoms in the Emergency Department, finding PE by CT angiography in 18% to 23% of patients (12, 13). Previously undiagnosed DVT and PE have also been identified by autopsy in patients dying at home or in a nursing home (14), and a case report described an asymptomatic individual with COVID-19 who presented with sudden death due...
to massive PE (15). Whether VTE rates are increased in non-hospitalized patients with COVID-19 is unknown, however.

Similarly, limited data exist concerning the risk of thromboembolic complications for patients with COVID-19 in the post-discharge/convalescence setting. One study noted that out of 1,368 patients discharged following a hospitalization related to COVID-19, 61 patients (4.4%) were re-admitted, 10 for a thrombotic event in venous or arterial territory (16).

**Extended thromboprophylaxis following hospitalization in non-COVID-19 patients**

Multiple studies have documented that a recent hospitalization is associated with an increased risk for VTE in the post-discharge setting. This increased risk for PE and DVT remains markedly elevated for at least the first month after hospital discharge (17). Although several trials have investigated whether an extended course of thromboprophylaxis with an anticoagulant can decrease this increased risk for VTE, none have shown a substantial improvement in the VTE rate (Table 1). There are unique aspects to each of the studies that may have contributed to the observed outcomes, however.

**Table 1. Clinical trials investigating thromboprophylaxis in patients hospitalized for acute medical illness.**

<table>
<thead>
<tr>
<th>Clinical Trial</th>
<th>Arms</th>
<th>Efficacy outcome(s)</th>
<th>Event rate for anticoagulant</th>
<th>Event rate for placebo</th>
<th>Comparisons†&lt;sup&gt; (95% CI)&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXCLAIM (18)</td>
<td>(1) Enoxaparin vs. (2) Placebo</td>
<td>Symptomatic VTE at 28 d</td>
<td>0.2%</td>
<td>1.0%</td>
<td>-0.75 (-1.19 to -0.32)</td>
</tr>
<tr>
<td>ADOPT (19)</td>
<td>(1) Apixaban (extended course) vs. (2) Enoxaparin (short course)</td>
<td>Total VTE&lt;sup&gt;‡&lt;/sup&gt; or VTE-related death</td>
<td>2.71%</td>
<td>3.06%</td>
<td>0.87 (0.62-1.23)</td>
</tr>
<tr>
<td>MAGELLAN (20)</td>
<td>(1) Rivaroxaban vs. (2) Placebo</td>
<td>Symptomatic non-fatal VTE at 35 d -or- CV death, MI, or ischemic CVA at 35 d</td>
<td>0.6%</td>
<td>0.7%</td>
<td>0.82 (0.47-1.43)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.8%</td>
<td>1.6%</td>
</tr>
<tr>
<td>APEX (21)</td>
<td>(1) Betrixaban vs. (2) Placebo</td>
<td>Symptomatic VTE by 42 d</td>
<td>0.9%</td>
<td>1.5%</td>
<td>0.64 (0.42-0.98)</td>
</tr>
<tr>
<td>MARINER (22)</td>
<td>(1) Rivaroxaban vs. (2) Placebo</td>
<td>VTE + VTE-related death -or- VTE, MI, CVA, or CV death</td>
<td>0.83%</td>
<td>1.10%</td>
<td>0.76 (0.52-1.09)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.56%</td>
<td>2.00%</td>
</tr>
</tbody>
</table>

* Efficacy outcomes reported in this table could be either primary or secondary outcomes, chosen to most closely reflect the study design developed in this protocol. Both MAGELLAN and APEX included an initial anticoagulant for 10 ± 4 days received by all patients, followed by anticoagulant vs. placebo for an additional ~25 days. ADOPT compared apixaban 2.5 mg twice daily for 30 days to enoxaparin 40 mg once daily for 6-14 days.

† EXCLAIM, absolute risk differences; ADOPT, MAGELLAN and APEX, relative risk; MARINER, hazard ratio.

‡ Total VTE includes symptomatic VTE and asymptomatic VTE, determined by screening ultrasounds of study participants.

EXCLAIM studied acutely ill medical patients ≥40 years of age with recently reduced mobility, treated with enoxaparin for 10 days followed by an additional 28 days of enoxaparin or placebo (18). The protocol was modified after interim analyses suggested lower than expected VTE rates to enroll only individuals at higher risk (age >75 yrs; history of VTE; active or previous cancer). The trial showed a decrease in the incidence of VTE, but primarily restricted to women, patients >75
years of age, and with level 1 immobility (18). MAGELLAN also treated patients with an initial 10 days of enoxaparin, and then randomized to rivaroxaban or placebo for an additional 25 days of therapy (20). Rivaroxaban reduced the risk of the primary outcome, symptomatic DVT/PE and asymptomatic DVT, but not of symptomatic VTE alone (20). APEX included a similar design with an initial 10 days of anticoagulant, followed by betrixaban or placebo for an additional 25–32 days (21). There was no significant difference between betrixaban and placebo for the primary outcome, symptomatic and asymptomatic DVT, although there was a decrease in symptomatic VTE (Table 1). MARINER compared 45 days of rivaroxaban to placebo in medically ill patients at an increased risk for VTE on the basis of a modified IMPROVE score of ≥4 (22). The decrease in symptomatic VTE and VTE-related death was not significant (Table 1).

Recent guidelines recommend against the routine use of extended thromboprophylaxis in medical patients following hospital discharge (23), although it is recognized that selected high-risk patients may warrant this approach. The COVID-19 post-discharge patient population, however, potentially represents such a novel high-risk group that might benefit from extended thromboprophylaxis. In particular, the noted increased risk that these patients exhibit for thromboembolic events while hospitalized (5-7), the autopsy data indicating a significant amount of thrombus affecting smaller vessels (14, 24), and the observations that this hospitalized patient population exhibits additional risk factors for VTE (e.g., older age, obesity) all support a study on post-discharge thromboprophylaxis in this patient population.

1.1.1 Thromboprophylactic therapy: rationale, potential benefits, and potential risks
For Stage 1 of this adaptive-design trial, we will investigate whether thromboprophylaxis with prophylactic-dose anticoagulant therapy can significantly decrease the risk for thromboembolic complications in patients with COVID-19 who are discharged from the hospital compared to matching placebo. In Stage 1, concomitant aspirin therapy (or other single-agent antiplatelet therapy) is not a contraindication for participation, and participants will be stratified based on whether they need to be treated with aspirin and WHO severity score (<5 vs. >= 5). The primary outcome will be a composite endpoint of venous thromboembolism, stroke, myocardial infarction, peripheral arterial thromboembolism, and all-cause death.

Potential risks associated with participation in this trial include bleeding complications, and patients with a clinical contraindication to anticoagulant therapy (e.g., gastroduodenal ulcer, major surgery within 14 days, ischemic stroke, intracranial bleed or surgery within 3 months, known hemorrhagic diathesis) or thrombocytopenia (platelet count <50,000/mcL) would be excluded from participation in the randomized study. Bleeding rates associated with the trials presented in Table 1 are shown in Table 2 below.
Table 2. Bleeding rates in clinical trials investigating thromboprophylaxis in patients hospitalized for acute medical illness.*

<table>
<thead>
<tr>
<th>Clinical Trial</th>
<th>Arms</th>
<th>Safety outcome(s)</th>
<th>Event rate for anticoagulant</th>
<th>Event rate for placebo</th>
<th>Comparisons† (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXCLAIM (18)</td>
<td>(1) Enoxaparin vs. (2) Placebo</td>
<td>Major bleeding</td>
<td>0.8%</td>
<td>0.3%</td>
<td>0.51 (0.12-0.89)</td>
</tr>
<tr>
<td>ADOPT (19)</td>
<td>(1) Apixaban (extended course) vs. (2) Enoxaparin (short course)</td>
<td>Major bleeding</td>
<td>0.47%</td>
<td>0.19%</td>
<td>2.58 (1.02-7.24)</td>
</tr>
<tr>
<td>MAGELLAN (20)</td>
<td>(1) Rivaroxaban vs. (2) Placebo</td>
<td>Major bleeding at 35 d or Clinically relevant bleeding at 35 d</td>
<td>1.1%</td>
<td>0.4%</td>
<td>2.9 (1.60-5.15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.1%</td>
<td>1.7%</td>
<td>2.5 (1.85-3.25), p&lt;0.001</td>
</tr>
<tr>
<td>APEX (21)</td>
<td>(1) Betrixaban vs. (2) Placebo</td>
<td>Major bleeding or Major or clinically relevant non-major bleeding</td>
<td>0.7%</td>
<td>0.6%</td>
<td>1.19 (0.67-2.12), p=0.55</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3.1%</td>
<td>1.6%</td>
<td>1.97 (1.44-2.68), p&lt;0.001</td>
</tr>
<tr>
<td>MARINER (22)</td>
<td>(1) Rivaroxaban vs. (2) Placebo</td>
<td>Major bleeding or Nonmajor clinically relevant bleeding</td>
<td>0.28%</td>
<td>0.15%</td>
<td>1.88 (0.84-4.23)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1.42%</td>
<td>0.85%</td>
<td>1.66 (1.17-2.35)</td>
</tr>
</tbody>
</table>

* MAGELLAN and APEX included an initial anticoagulant for 10 ± 4 days received by all patients, followed by anticoagulant vs. placebo for an additional ~25 days. ADOPT compared apixaban 2.5 mg twice daily for 30 days to enoxaparin 40 mg once daily for 6-14 days.
† EXCLAIM, absolute risk differences; ADOPT, MAGELLAN and APEX, relative risk; MARINER, hazard ratio.

2. Study Design

2.1 Overall Study Design

This platform trial is an adaptive design protocol intended to determine the optimal antithrombotic strategy to prevent thromboembolic complications in patients hospitalized with COVID19 following discharge from the hospital. The first Stage is a randomized, double-blind, placebo-controlled study comparing a prophylactic dose anticoagulant with matching placebo (Figure 1).

Subsequent Stages of this adaptive protocol will incorporate new data as it becomes available in this rapidly evolving clinical and research environment. Each Stage will be developed as a separate, detailed Appendix to the Master Protocol. Each Stage will use concurrent control arm data, and controls from earlier Stages will not be used in subsequent Stages. A full Statistical Analysis Plan will be developed for each Stage, and each new Stage will be submitted with the Statistical Analysis Plan for review by the FDA before implementation.

2.2 Randomization

Randomization will be performed for study participants as close to the time of hospital discharge as possible. Hospitalized patients may be screened and approached about the study up to 48 hours prior to hospital discharge, but final enrollment and randomization should occur as close to the time of discharge as possible. In Stage 1, participants will be randomized in a 1:1 ratio using an online randomization system to either Arm A (prophylactic anticoagulant therapy); or Arm B (matching
placebo). The randomization scheme will be determined by the study phase and its associated group of intervention arms. Randomization for Stage 1 will be stratified by (1) concomitant use of a single antiplatelet agent, and (2) a maximal score of 5 or greater vs. a score of less than 5 by the WHO Ordinal Index (Table 3).

Table 3. **WHO ordinal scale for clinical improvement**  

<table>
<thead>
<tr>
<th>Patient State</th>
<th>Score</th>
<th>Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uninfected</td>
<td>0</td>
<td>No clinical or virological evidence of infection</td>
</tr>
<tr>
<td>Ambulatory</td>
<td>1</td>
<td>No limitation of activities</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Symptomatic: Limitation of activities</td>
</tr>
<tr>
<td>Hospitalized: Mild</td>
<td>3</td>
<td>Hospitalized; no oxygen therapy</td>
</tr>
<tr>
<td>Hospitalized: Severe</td>
<td>5</td>
<td>Non-invasive ventilation or high-flow oxygen</td>
</tr>
<tr>
<td>Hospitalized: Severe</td>
<td>6</td>
<td>Intubation &amp; Mechanical ventilation</td>
</tr>
<tr>
<td>Hospitalized: Severe</td>
<td>7</td>
<td>Ventilation and additional organ support – pressors, RRT, ECMO</td>
</tr>
<tr>
<td>Death</td>
<td>8</td>
<td>Death</td>
</tr>
</tbody>
</table>

2.3 **Study Interventions**

This master protocol study will open by comparing a prophylactic anticoagulant therapy in Arm A and matching placebo in Arm B.

2.4 **Biorepository**

A biorepository will be established to biobank samples for further studies of biomarkers of thrombotic risk and inflammation. Centers capable of collecting, processing, and shipping samples may opt in for collecting and biobanking these samples from eligible participants. There will be a nested design to the biobanking strategy, so that sites can participate based on level of expertise, staffing, and interest. The initial samples proposed for the biorepository are listed in Appendix 3. Biorepository specimens may change during different stages of this adaptive design protocol.

3. **Objectives and Purpose**

The overarching objective of this adaptive research trial design is to iteratively learn which antithrombotic strategy is best for the prevention of thromboembolic complications in patients with COVID-19 who have been hospitalized for two or more days and are being discharged from the hospital, during the post-discharge/convalescence phase of the illness. At each Stage of the trial, the goal is to determine the superior approach that should be considered standard care for this patient population. Subsequent stages will introduce alternative strategies and/or designs that will be compared to this new standard of care in an iterative fashion. This process will continue until there are no new strategies that replace the standard of care.
The primary outcome for Stage 1 will be a composite endpoint of venous thromboembolic events, including new, symptomatic proximal or distal deep vein thrombosis affecting the upper and/or lower extremities, pulmonary embolism, or thrombosis of other veins (e.g., cerebral sinus veins, splanchnic veins); arterial thromboembolic events, including new ischemic stroke, myocardial infarction, mesenteric or peripheral arterial thromboembolism; and all-cause mortality for up to 30 days after randomization. This primary outcome is expected to be similar across all stages of this study, although it is possible that changes could be introduced on the basis of results accrued during the study.

Primary Objective: In COVID-19 patients who have been hospitalized, the primary objective of this master trial is to determine the optimal antithrombotic strategy to minimize the composite endpoint of venous and arterial thromboembolic outcomes, and all-cause mortality. Stage 1 of this trial will compare the effects of treatment beginning at the time of discharge from the hospital with either (i) anticoagulation at a prophylactic dose, or (ii) no anticoagulation on the primary outcome for up to 30 days after randomization.

Secondary Objectives:

Secondary Objective 1: To compare the effects of treatment beginning at the time of discharge from the hospital with either Arm A or Arm B on the incidence of the composite outcome at 45 days and at 90 days after randomization.

Secondary Objective 2: To compare the effects of treatment beginning at the time of discharge from the hospital with either Arm A or Arm B on the incidence of new, symptomatic VTE (inclusive of DVT, PE, or other venous thrombosis) for up to 30 days after randomization.

Secondary Objective 3: To compare the effects of treatment beginning at the time of discharge from the hospital with either Arm A or Arm B on the incidence of new, symptomatic ATE (inclusive of ischemic stroke, MI, or peripheral arterial thromboembolism) for up to 30 days after randomization.

Exploratory Objectives:

Exploratory Objective 1: To compare the effects of treatment beginning at the time of discharge from the hospital with either Arm A or Arm B on the incidence of all-cause rehospitalization for up to 90 days after randomization.

Exploratory Objective 2: To compare the effects of treatment beginning at the time of discharge from the hospital with either Arm A or Arm B on the incidence of all-cause mortality for up to 30 days after randomization.

4. Study Design and Endpoints

Following Stage 1, subsequent stages will incorporate recommendations from the DSMB based on the accrued in-trial data at prespecified timepoints or at selected milestones of participants accrued into the study. Adaptive changes may impact the treatment arms (e.g., modifications to the antithrombotic agent or regimen, duration of therapy), patient eligibility (e.g., identification of unique patient characteristics associated with a higher or lower risk of the primary outcome), endpoints (e.g., addition of alternative endpoints), or any combination of these variables.
4.1 Description of Study Design: Stage 1

The Stage 1 study is a randomized trial of COVID-19 positive patients who have been hospitalized and are ready for discharge from the hospital. All inclusion and exclusion criteria (Sections 5.1 and 5.2, below) must be met prior to enrollment and randomization. In Stage 1, participants will be randomized to either Arm A (prophylactic anticoagulation), or Arm B (matching placebo) (Figure 1). Potential study participants will be identified through review of inpatient census data at each site.

Figure 1. COVID-19 Post-Discharge Clinical Trial Stage 1. Participants will be enrolled in the Study prior to discharge from the hospital and randomized to one of two Arms (this general design may change with adaptations during the course of the study). Screening and enrollment will occur prior to discharge from the hospital, with randomization occurring as close to discharge as possible (randomization identified as the encircled “R”, occurring immediately prior to discharge, identified by the vertical dashed line). Follow-up encounters for the primary outcome will occur on Days 2±1, 10±3, 20±3, and 30±10. Two additional follow-up encounters will occur for secondary outcomes on Days 45±14 and 90±14. The Day 45 follow-up encounter will also be included to ensure the 2nd biorepository specimens have been collected for those participating in this part of the study.

The initial follow-up encounter, which will be conducted by the Call Center via the participant’s preferred method (electronic or phone call), will occur within 2±1 days following discharge from the hospital, to confirm medication compliance and perform an initial assessment of outcomes. Subsequent encounters, which will also be conducted by the Call Center electronically or by phone, will occur at 10±3, 20±3, and 30±10 days after enrollment. With each encounter, assessments of medication compliance and outcomes will be performed. Two additional encounters will occur after completion of the primary outcome, at 45±14 and 90±14 days after enrollment, to determine if there is an increased risk for thromboembolic complications following hospital discharge that extends for a longer period of time than 30 days and to facilitate/confirm collection of the 2nd set of biorepository specimens. All contacts will be scripted to ensure that all information is uniformly collected.
4.2  Study Endpoints for Stage I

4.2.1 Primary Study Endpoints
At day 30, a binary composite endpoint of venous and arterial thrombotic complications—including new, symptomatic proximal, or distal DVT of the upper or lower extremities, PE, and new thrombosis of other veins (including cerebral sinus and splanchnic veins)—ischemic stroke, myocardial infarction, other arterial thromboembolism (e.g., mesenteric or acute limb ischemia), and all-cause mortality will be the primary study endpoint.

4.2.2 Key Secondary and Exploratory Endpoints
Key secondary endpoints include the following.

1. Composite endpoint of venous thromboembolic events, including symptomatic DVT of the upper or lower extremities, symptomatic and/or clinically relevant PE, and other symptomatic venous thrombosis, including cerebral sinus and splanchnic vein thrombosis at day 30
2. Composite endpoint of arterial thromboembolic events, including symptomatic ischemic stroke, myocardial infarction, and other symptomatic arterial thromboembolic events at day 30
3. The composite endpoint for the primary outcome at days 45 and 90 following discharge from the hospital

Exploratory endpoints include the following.

1. All-cause mortality at day 30 following discharge from the hospital
2. All-cause re-hospitalization at day 90 following discharge from the hospital

4.2.3 Safety Endpoints for Stage 1
Safety endpoints will include (1) major bleeding, as defined by the ISTH, and (2) clinically-relevant, non-major bleeding, also as defined by the ISTH. Criteria for major bleeding, and for CRNMB are provided below

1. Major bleeding
   a. Fatal bleeding
   b. Bleeding into a critical area or organ (e.g., intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal)
   c. Bleeding causing a fall in the hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells
2. Clinically-relevant, non-major bleeding
   a. Bleeding requiring medical intervention by a healthcare professional
   b. Bleeding leading to hospitalization or an increase in the level of care
   c. Bleeding prompting a face-to-face (i.e., not just a telephone or electronic communication) evaluation

4.2.4 Adjudication of outcome events
All patient-reported events will be investigated by the Clinical Coordinating Center, including obtaining information from healthcare facilities where the patient received treatment. An independent, central adjudication committee (ICAC) will review and adjudicate events in a blinded manner without knowledge of treatment allocation. During the study period, the ICAC will adjudicate
all suspected occurrences of venous or arterial thromboembolic events, ischemic stroke, acute myocardial infarction, deaths, and re-hospitalization. The ICAC will also review all suspected episodes of bleeding and categorize adjudicated bleeding as major, clinically-relevant non-major, or minor bleeding. The Committee will be provided with all relevant documentation related to the events. The criteria and definitions of the study outcomes, as well as the procedures followed by the Committee, will be described in an adjudication manual which will be provided to the ICAC members prior to the first meeting.

5. Study Enrollment

5.1 Inclusion Criteria
The inclusion criteria for Stage 1 of this adaptive protocol are listed below. Potential study participants will be identified during hospitalization and reviewed for inclusion/exclusion criteria. Per the adaptive trial design strategy, these criteria may change after the first and subsequent analyses of in-trial accrued data.

- Age ≥ 18 years
- PCR-positive COVID-19 infection
- Hospitalized for 48 or more hours

5.2 Exclusion Criteria
The exclusion criteria for Stage 1 of this adaptive protocol are listed below. These are potentially subject to change based on the adaptive trial design and analyses of in-trial accrued data.

- Existing indication for anticoagulation, either therapeutic or prophylactic dose
- Contraindication to antithrombotic therapy, such as
  a) ischemic stroke, intracranial bleed, or neurosurgery within 3 months
  b) Known bleeding within the last 30 days requiring emergency room presentation of hospitalization
  c) Known major surgery within 14 days (at least 1 hour and/or requires general anesthesia)
  d) Inherited or active acquired bleeding disorder
- Platelet count < 50,000/mcL
- Hemoglobin < 8 gm/dL
- Pregnancy
- Prison inmate
- Life expectancy less than 90 days
- Unwilling or unable to provide informed consent / unwilling or unable to complete the study protocol
- Other criteria related to arm-specific appendices developed as adaptations to the trial.

5.3 Vulnerable Subjects
As noted in the Exclusion Criteria, this study will not enroll children < 18 years of age, pregnant women, or prisoners.

5.4 Strategies for Recruitment and Retention
The Protocol Implementation Committee (PIC) will respond to the evolving landscape of the pandemic by leveraging the network of networks already established within ACTIV-4, including all sites participating within the networks. As is currently evident, the pace of the pandemic varies across different areas within the United States, based on propagation patterns, local social
distancing rules, and compliance with those rules. In addition, the PIC will also be monitoring the course of the pandemic across the world to identify regions where the number of potential study subjects would make rapid recruitment feasible (e.g., Brazil). By monitoring the evolution of the infection, the PIC will place sites on hold when disease activity wanes in their geographic areas and activate new sites when the local rate of new COVID-19 cases exceeds a threshold making recruitment feasible.

Screening and enrollment will occur within the hospital setting, targeting patients being considered for discharge within 48–72 hrs. Providers managing these patients will be made aware of the study, and the research team at each site will review the list of inpatients to identify potentially eligible patients for the study. Study participants will be provided with study drug at the time of discharge from the hospital, with detailed instructions for taking the medication. At those sites with the capability to process and store biospecimens, those patients who agree to participate will be asked to provide samples for preparation of plasma, serum, and genomic DNA, as described below.

The local study team will collect relevant contact information for the participant, participant’s spouse or partner, one contact individual who is not related to the participant to maintain contact, and the participant’s Primary Care Physician. The local study team will inform the participant about the Call Center’s role and, if possible, put the phone number in the participant’s phone so they recognize the caller later. The participant will be asked to sign a Release of Records form for the PCP or other hospital. This form will have an expiration date 150 days after randomization.

One encounter with the study participant will occur at one to three days after discharge, to confirm medication compliance and collect information concerning any early outcome events. Five additional encounters for confirming compliance with the protocol and collecting outcome information will occur at 10±3 days, 20±3 days, 30+10 days, 45+14 days, and 90+14 days from initiation of the study. These visits may be set up to be electronic only (e-mail, text, chat) or by telephone, depending on which approach works best for the study team and the individual study participant. The study is completed within approximately 90 days of initiation.

Enrollment and retention of economically-disadvantaged individuals. The overall success of this study is critically dependent on the ability of all patients who meet inclusion/exclusion criteria to participate in the study. Populations historically affected by health disparities, including non-Hispanic Blacks and Hispanics, have been shown in several studies to be disproportionally affected by and hospitalized with COVID-19 (25, 26). These populations are also disproportionally affected by economic disparities, which can lead to difficulties with obtaining costly outpatient medications, leading to non-compliance. Consequently, the first stage of this study will provide the anticoagulant and the matching placebo to eliminate this potential reason for not participating in the study. This approach will ensure that this study is relevant to the entire range of patients hospitalized with COVID-19.

5.5 Duration of Study Participation

Study participation lasts from the time the participant is enrolled into the study until 90 days from randomization or when an outcome event occurs, whichever is earlier.

Total Number of Participants

Sample size calculations for Stage 1 are described in Section 7. Initial power calculations using conservative event rates from post-hospital extended duration VTE prophylaxis trials in medically ill patients selected for increased risk suggest that 2,660 participants per arm will be required to determine if thromboprophylaxis with an anticoagulant is superior to no anticoagulant.
thromboprophylaxis. There will be interim monitoring to enable early stopping for futility, efficacy, or safety.

5.6 **Participant Withdrawal or Termination**

5.6.1 **Reasons for Withdrawal or Termination**

Study participants are free to withdraw from participation in the study at any time upon written request. The site PI will notify the Clinical Coordinating Center of all withdrawals from the study. Study participants who withdraw consent will not have additional information collected after they withdraw from the study.

A site investigator may withdraw a study participant from the study on the basis of either:

- Any clinical adverse event, laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the patient.
- The participant meets an exclusion criterion, either newly developed or not previously recognized (e.g., new thrombocytopenia, renal insufficiency), that precludes further study participation.

5.6.2 **Premature Termination or Suspension of Study**

All deaths, SAEs, and related clinical events within the study period will be reviewed by the DSMB. The decision to stop or suspend the study will be made by the DSMB after considering the totality of the data and the benefit-risk of continuing the study. These decisions could lead to an adaptive change in the protocol, with one arm of the study being discontinued or modified/changed to an alternative approach.

The study may resume once concerns about safety, protocol compliance, and data quality are addressed and satisfy the IRB, the DSMB, and the sponsor.

5.7 **Study Agents**

Study agents for Stage 1 include:

1) Prophylactic anticoagulant, defined as a dose intended for the prevention of VTE; and
2) Matching placebo

Subsequent adaptations of this study may focus on modifications to the antithrombotic strategy, specific subsets of patients identified as being higher-risk for thrombotic complications, or other changes, as outlined in Figure 1.

5.8 **Duration of Therapy**

Duration of the thromboprophylaxis period will be 30 days, beginning at the time of discharge from the hospital. Primary outcome will be assessed by 30 days after enrollment. Study participants will be followed for an additional 60 days after discontinuation of thromboprophylaxis (total duration of study participation = 90 days).

Study agents for subsequent stages will be determined based on the adaptive design of the trial.
6. **Study Procedures and Schedule**

### 6.1 **Study Schedule**

<table>
<thead>
<tr>
<th>Activity</th>
<th>Baseline screening (Days -2 to 0)</th>
<th>Enrollment (Day 0)</th>
<th>Randomization (Day 0)</th>
<th>Day 2±1</th>
<th>Day 10±3</th>
<th>Day 20±3</th>
<th>Day 30±10</th>
<th>Day 45+14</th>
<th>Day 90+14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility Assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SARS-Cov 2 test positive</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine/eGFR</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrollment &amp; Randomization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline data collection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-dimer at time of enrollment</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy testing (if necessary)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Drug Administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study drug provided</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient education</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study drug taken</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Procedures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm study drug compliance</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome assessment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AE assessment and reporting</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Assessments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-dimer</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biorepository samples</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 6.2 **Laboratory Procedures/Evaluations**

All study participants will have a D-dimer drawn on the day of enrollment into the study. In addition, sites able to collect and process samples for a biorepository will collect samples at two timepoints:

1. On Day 0, prior to initiation of the study drug
2. Between Days 30 and 45, after the patient has discontinued the study drug.

The proposed samples to be collected for the biorepository during Stage 1 of the study are reviewed in Appendix 3. Samples collected for the biorepository may change to accommodate the adaptive design of the study in response to changes in trial design.

#### 6.2.1 **Study encounters**

Baseline screening and enrollment (occurs Day –2 up to Day 0)
1. Inclusion/exclusion criteria reviewed—including a pregnancy test, if necessary—and eligibility for the trial determined
2. Patient enrolled into the study and informed consent obtained
3. Patient provided with information concerning the study, contact information, etc.
4. Occurs during last few days of hospitalization

Encounter 1: Enrollment & randomization (Day 0)
1. Patient randomized to study drug
2. Information concerning the study, contact information, etc., reviewed with the patient
3. Encounter occurs on day of discharge from the hospital

Encounter 2: First follow-up (Day 2±1)
1. First post-discharge encounter
2. Confirm taking study medication, review for any outcome events, adverse events

Encounter 3: Day 10±3
1. Second post-discharge encounter
2. Confirm taking study medication, review for any outcome events, adverse events

Encounter 4: Day 20±3
1. Third post-discharge encounter
2. Confirm taking study medication, review for any outcome events, adverse events

Encounter 5: Day 30+10
1. Fourth post-discharge encounter
2. Confirm taking study medication, review for any outcome events, adverse events
3. Participant will stop taking the study medication on Day 30
4. Events occurring up to this encounter will be included in the primary outcome
5. Make and confirm arrangements for second biorepository encounter

Encounter 6: Day 45+14
1. Fifth post-discharge encounter
2. Review for any outcome events, adverse events
3. Confirm second biorepository encounter has occurred

Encounter 7: Day 90+14 encounter
1. Sixth and last post-discharge check-in
2. Review for any outcome events, adverse events
3. Follow-up ends after the Day 90 encounter

6.3  Concomitant Medications, Treatments, and Procedures
Concomitant medications taken during study participation will be recorded on the case report forms (CRFs). Concomitant medications to be recorded are:
1. Antiplatelet therapies (e.g., aspirin, clopidogrel)
2. Anticoagulant medications that may be prescribed to the participant after randomization and discharge from the hospital (e.g., a new prescription introduced by an outpatient provider, without notification of the study team, in response to a clinical concern about thrombosis risk or symptoms)
3. Other therapies that may impact arm-specific appendices
6.4 **Expedited Critical and Major Event Reporting**

All efficacy and safety outcome events will be assessed and documented in the patients’ study records. Events meeting the DSMB-specified severe criteria must be reported immediately and no later than 72 hours from occurrence. These events include major bleeding (fatal bleeding or symptomatic bleeding in a critical area or organ), including intracranial hemorrhage.

The ACTIV-4 trial will have a common policy for reporting adverse events to ensure that all events are assessed quickly and are submitted to the DSMB, IRB(s), and other groups as needed (e.g., FDA), following each group’s reporting guidelines and timelines. Sites are required to follow their local guidelines for adverse event and unanticipated problem reporting.

6.5 **Data and Safety Monitoring Plan and Study Halting Rules**

The ACTIV-4 will have a single Data and Safety Monitoring Plan with a single Data and Safety Monitoring Committee to review all research carried out within the master protocol.

7. **Statistical Considerations**

7.1 **Statistical and Analytical Plans (SAP)**

This section provides an overview of the design and main analyses for the key endpoints. A separate SAP will be constructed for the DSMB review process. Additionally, a final SAP will be formalized and agreed upon by the study team prior to the completion of the study and before database lock. The final SAP will include additional details about the statistical analyses, including analysis of specified populations, plans for addressing missing data, and planned sensitivity analyses.

7.2 **Power and Sample Size Calculations**

The primary analysis for this randomized trial will be an intention-to-treat comparison of a composite endpoint (CE) of venous thromboembolic events, including new, symptomatic proximal or distal deep vein thrombosis affecting the upper and/or lower extremities, pulmonary embolism, or thrombosis of other veins (e.g., cerebral sinus veins, splanchnic veins); arterial thromboembolic events, including new ischemic stroke, myocardial infarction, mesenteric or peripheral arterial thromboembolism; and all-cause mortality for up to 30 days after randomization across the intervention arms. This binary primary endpoint was used to power the study.

The MARINER trial (21) reported a 2% event rate for a combined outcome of VTE, MI, CVA, or CV deaths in the placebo group. These rates are expected to be higher in COVID-19 patients who are discharged from the hospital. Recent information from patients discharged alive from the University of Pittsburgh Medical Center suggests that the 30-day mortality rate in this population could be as high as 4%. To be conservative, 4% was used as the expected CE rate of events for the no anticoagulant arm. An effect size of 35% percent risk reduction (risk ratio = 0.65) in the anticoagulant group compared to no anticoagulant group was used to calculate the expected sample size for the study.

The analysis will use a group-sequential two-sample two-sided Z-test for proportions with pooled standard deviation to test the primary hypothesis at overall significance level alpha = 0.05. Four equally spaced interim analyses and one final analysis will use Haybittle-Peto boundaries to guide the efficacy reviews (27, 28). In order to ensure an 80% power to detect a CE rate reduction of 35% through anticoagulation use, the study needs to enroll at least 2,530 participants per arm. Since the primary outcome is observed within 30 days of follow-up, the loss to follow-up and withdrawal of
consent rates should be low, and it is estimated that CE will be missing on a maximum of 5% of the participants. Therefore, the sample size required for this study will be approximately 2,660 per arm. The sample size has been calculated using 2,000 simulations in PASS 13 [PASS 13 Power Analysis and Sample Size Software (2014). NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass].

7.3 Primary Outcome Analysis
The ITT principle will be used for the treatment comparisons of trial outcomes such that subjects randomized to the treatment arms will be included in the analysis. Trial follow up will begin at the time of randomization. In other words, Day 0 is the day of randomization.

As a primary approach, the primary endpoint will be compared between two arms using a two-sample Z-statistic for proportion (standardized difference between proportion having CE in anticoagulant arm and matching placebo arm, positive difference favoring anticoagulant arm).

For Stage 1, the CE rates will also be modeled using a log-binomial regression model with treatment arm as the independent variable and adjusting for trial stratification variables (i.e., antiplatelet use; WHO ordinal scale score). Secondary analyses of this endpoint will include adjustment D-dimer levels, intensive care unit stay, patient characteristics, and demographic factors, including race and ethnicity. The matching placebo arm will serve as the “reference group” in this model, and the primary outcome analysis will involve testing whether the coefficient for each active treatment group relative to the reference group is equal to 0, or equivalently, whether the adjusted relative risk for anti-coagulant arm is equal to 1. The adjusted relative risk and the related confidence interval will be provided.

In addition, unadjusted event rates for each treatment group, and relative risk and the absolute risk differences with confidence intervals, will be calculated and presented. Kaplan-Meier cumulative incidence curves will also be presented to allow visualization of the patterns of time to first events. As a sensitivity analysis, a modified intention-to-treat analysis, excluding all randomized participants who fail to initiate treatment, will be conducted.

7.4 Tabulation of Individual Response Data
The composite outcome evaluated will be tabulated and broken down by component (e.g., death, pulmonary embolus, symptomatic DVT, myocardial infarction, etc.). Note that all clinical endpoint events that occur during the 30-day treatment period will be collected regardless of whether a patient discontinues therapy or experiences an initial clinical event. As a result, some participants may experience more than one component of the primary endpoint. Event rates and relative risks and the absolute risk difference between treatment groups will be calculated with their confidence intervals for each of the defined secondary endpoints.

7.5 Sub-group Analyses
A select number of subgroup analyses will be performed based on pre-specified baseline factors that potentially modify the effect of treatment. The main subgroup analyses will be done for antiplatelet use and no antiplatelet use groups, and for severity of illness during hospitalization, based on the WHO ordinal scale score (score < 5, vs. ≥ 5). Additional subgroup analysis will include D-dimer (for example, multiples greater than the upper limit of normal), age (< 60 years, ≥ 60 years), sex, race/ethnicity (white non-Hispanic, Black non-Hispanic, Hispanic, other), and country. When outcomes are rare within subgroups, the categories may be amalgamated (e.g., White vs. Others, US vs. Other countries). The rate of the 30-day primary composite outcome and the safety
outcomes will be compared by assigned treatment within pre-defined subgroups. In addition, an assessment of whether there is evidence that each subgroup variable modifies treatment effectiveness will be performed by creating a log-binomial regression model including the subgroup variable, treatment assignment, and the interaction between the subgroup variable and treatment assignment, and evaluating the magnitude of the interaction term.

7.5.1 Safety Analyses
The rates of safety outcomes listed in section 2.3 (e.g., ISTH major bleeding and the rate of ISTH clinically relevant non-major bleeding (CRNMB)) during the 30-day treatment period and during the additional 60-day safety follow up period between the two arms will be compared. The proportion of patients in each assigned treatment group who experience each safety event, the relative risk, and the absolute risk difference will be calculated from the observed data, and confidence intervals will be calculated. Analyses of the bleeding outcomes that occur during the full 90-day follow-up period (i.e., 30-day treatment period plus the 60-day safety follow-up) will also be conducted as part of the trial safety analyses.

7.5.2 Adherence and Retention Analyses
Receipt of planned therapy will be recorded on electronic case report forms. The proportion of patients evaluated with less than 30-days of follow-up (the primary outcome assessment time) will be tabulated. Every effort will be made to re-contact patients who are unreachable. Due to the short timeline of trial participation, there should be excellent patient retention. A thorough evaluation of missing data patterns will be undertaken. Baseline characteristics of patients with missing primary outcome data will be compared to those with complete data; factors associated with missing primary outcome data will be identified using logistic regression. Missing follow-up data will not be imputed for the analysis of the primary hypothesis unless critical issues are identified.

7.5.3 Baseline Descriptive Statistics
A limited number of demographic, clinical history, symptom, and biomarker variables will be collected for each patient at baseline. The distribution of each variable will be examined. All variables will be summarized using appropriate central tendency (mean/median) and spread measures (standard deviation, 25th and 75th percentiles, or range) for continuous variables and frequency and percent for categorical variables. Baseline characteristics will be examined with respect to assigned treatment group to verify randomization balance.

7.5.4 Planned Interim Analysis, Futility, and Efficacy
An independent data safety and monitoring board (DSMB) will review all interim analyses prepared by an unmasked statistician. The trial design planned for 4 interim analysis and a final analysis. At each interim analysis cumulative primary outcome data, and potentially the secondary analyses, will be presented to the DSMB. A Haybittle-Peto-type boundary with a p-value of 0.001 will be used as the guideline to stop based on efficacy.

Assessments of futility will be conducted at the same time as the reviews for efficacy. The study team will present a number of analyses based on optimistic, neutral, and pessimistic priors to assess the probability that Arm A is better than Arm B by 0%, 1%, and 2% for the 30-day primary endpoint. Additionally, Bayesian analysis on the risk ratio scale will evaluate the posterior probability that Arm A vs. Arm B has a relative risk for the CE of 1.00 and 0.65 under optimistic, neutral, and pessimistic priors (29).
7.5.5 Safety Review

Safety monitoring will be continuous. In addition to examining the rate of ISTH major bleeding and the rate of ISTH clinically relevant non-major bleeding (CRNMB) in each of the treatment arms, monitoring will include unacceptable toxicity, defined as major bleeding, including hospitalization, and all-cause mortality. Prior studies have shown that the rate of major bleeding will be very low. The degree of evidence about differences in risk of unacceptable toxicity from accruing data will be addressed on a regular and pre-determined basis (e.g., every 3 months) and will be shared with the DSMB. Unadjusted safety event rates for each assigned treatment group, and relative risks and the absolute risk differences with 95% confidence intervals, will be calculated and presented to the DSMB for each of the specified safety outcomes. Additionally, participants with safety events will be categorized in comparison to those without the safety events using a logistic regression to identify if the safety event was associated with any particular participant characteristics to identify high-risk groups, which will potentially inform DSMB of changing the inclusion criteria.

If safety issues arise, the DSMB will use their clinical and statistical judgement to assess the potential risks relative to the potential benefits. The DSMB may also examine the safety and efficacy data in subgroups known to be high risk for bleeding such as those with older age and/or higher BMI. The DSMB will use all available information to make recommendations to the NHLBI. The DSMB can recommend that the Post-discharge COVID-19 trial should continue as proposed, that one treatment arm or more may be dropped, that the trial protocol should be modified, or that the trial should be terminated early for safety reasons. At any of the safety reviews, the DSMB can request further statistical evaluation of the safety data to make a decision. Only the DSMB and those individuals invited to the DSMB closed-session are permitted to examine outcomes by assigned treatment group. The DSMB will evaluate the rates of the primary endpoint and the safety endpoints by assigned treatment groups overall and within pre-specified subgroups.

7.5.6 Subgroup Analyses based on Anti-Platelet Use, WHO Severity Score, and Other Pre-specified Characteristics

Beyond its primary aim, a major interest of the trial is to address the effect of anticoagulant separately within antiplatelet users and non-users. The primary analysis will be repeated within each of these subgroups. The pre-specified subgroups include

- WHO severity score (below five vs. five or above)
- ICU stay,
- age,
- sex,
- race/ethnicity, and
- country of enrollment.

7.5.7 Analyses of Duration of Treatment

The optimal length of treatment is not well-understood in this clinical setting. Hence, the analyses will examine the timing of clinical thrombotic events and safety hemorrhagic events based on the accruing data. Kaplan-Meier curves will be created to assess the time to the first thrombotic event and the time to the first hemorrhagic event, and Nelson-Aalen cumulative hazard curves will be used to assess the cumulative number of events.
8. Measures to Minimize Bias

8.1 Enrollment/Randomization

Enrollment

1. Hospitalized patients confirmed COVID-19 positive are screened daily for inclusion/exclusion criteria. Any patient who meets all inclusion criteria and no exclusion criteria will be approached for enrollment.

2. Patients remain in the intention-to-treat group.

Randomization

Randomization assignments are performed for patients at baseline visit. Randomization will be done with equal probability across the arms for which the participant is eligible. For Stage 1, randomization stratification will be done by anti-platelet use (yes/no) and WHO severity score (<5 / >=5).

The randomization scheme will be determined by the study Stage and its associated group of intervention arms. Randomization should obviate the need for additional adjustment factors, but if pre-specified demographic or clinical characteristics are unbalanced with respect to treatment group, an adjustment will be considered during the analyses phase; these characteristics include but are not limited to age, sex, race, ethnicity, BMI, and, potentially, country.

9. Source Documents and Access to Source Data/Documents

ACTIV-4 will have uniform policies describing what source documents are, how to make corrections, and who can access them.

10. Quality Assurance and Quality Control

ACTIV-4 will have common policies for quality assurance at the data entry level and site monitoring.

11. Ethics/Protection of Human Subjects

11.1 Ethical Standard

The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.

11.2 Institutional Review Board

The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study. All changes to the consent form will be IRB approved; a determination will be made regarding whether previously consented participants need to be re-consented.
11.3 Informed Consent Process

11.3.1 Consent/Assent and Other Informational Documents Provided to Participants
Consent forms describing in detail the study agent, study procedures, and risks are given to the participant, and written documentation of informed consent is required prior to starting intervention/administering study product.

A written consent will be sought from every participant via a face-to-face consenting process or remotely by using a REDCap based e-consent option pending IRB approval of this protocol.

11.3.2 Consent Procedures and Documentation
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Informed consent will be obtained following institutional COVID-19 policy to protect study staff.

An extensive discussion of risks and possible benefits of participation will be provided to the participants and their families. Consent forms will be IRB-approved and the participant will be asked to read and review the document. The investigator will explain the research study to the participant and answer any questions that may arise. Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing. The participants may withdraw consent at any time throughout the course of the trial. A copy of the signed informed consent document will be provided to participants. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.

11.4 Posting of Clinical Trial Consent Form
The informed consent form will be posted on the Study website after the clinical trial is closed to recruitment, and no later than 60 days after the last study visit by any subject, as required by the protocol.

11.5 Participant and Data Confidentiality
ACTIV-4 has adopted uniform policies for protecting the privacy of participants and maintaining confidentiality.

Information about study participants will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Those regulations require a signed subject authorization informing the subject of the following:

- What protected health information (PHI) will be collected from participants in this study
- Who will have access to that information and why
- Who will use or disclose that information
- The rights of a research subject to revoke their authorization for use of their PHI.

In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains the ability to use all information collected prior to the revocation of subject authorization. For participants that have revoked authorization to collect or use PHI, attempts
should be made to obtain permission to collect at least vital status (i.e., that the subject is alive) at
the end of their scheduled study period.

Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples
and genetic tests in addition to the clinical information relating to participants. Therefore, the study
protocol, documentation, data, and all other information generated will be held in strict confidence.
No information concerning the study or the data will be released to any unauthorized third party
without prior written approval of the sponsor.

The study monitor, other authorized representatives of the sponsor, and representatives of the IRB
or pharmaceutical company supplying study product may inspect all documents and records
required to be maintained by the investigator, including but not limited to, medical records (office,
clinic, or hospital) and pharmacy records for the participants in this study. The clinical study site will
permit access to such records.

The study participant’s contact information will be securely stored at each clinical site for internal
use during the study. At the end of the study, all records will continue to be kept in a secure location
for as long a period as dictated by local IRB and Institutional regulations.

Participant identifying information will be collected via electronic survey, and will be stored in secure
encrypted servers at the University of Pittsburgh. All data will be streamed via secure API to the
project clinical trial management system. Identifiers are required in both of these locations to enable
electronic outreach to participants for the purpose of self-reported data collection. The participant’s
name, mobile phone number, address, and contact information will only be housed on a temporary
basis to allow for follow-up during the course of the trial. These data will be maintained until
database lock at the end of the trial, at which point they will be destroyed, unless the participant has
agreed to be contacted for future research.

Study participant research data, which is for purposes of statistical analysis and scientific reporting,
will be transmitted to and stored at the University of Pittsburgh Data Coordinating Center. This will
not include the participant’s contact or identifying information. Rather, individual participants and
their research data in the central database will be identified by a unique study identification number.
The study data entry and study management systems used by clinical sites will be secured and
password protected. At the end of the study, all study databases will be de-identified and archived
at the NIH designated data repository.

12. Data Handling and Record Keeping

12.1 Data Collection and Management Responsibilities

Initial data collection is the responsibility of the clinical trial staff under the supervision of the site PI.
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of
the data reported. Follow up data will be collected electronically from the participant’s self-report
and by study staff via telephone. Responsibility for the accuracy, completeness, and timeliness of
data collected by telephone is under the supervision of the Coordinating Center investigators who
are responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data
reported.
Copies of the electronic CRF (eCRF) will be provided for use as source documents and maintained for recording data for each participant enrolled in the study. Data recorded in the eCRF derived from source documents should be consistent with the source documents or the discrepancies should be explained and captured in a progress note and maintained in the Coordinating Center’s official electronic study record.

12.2 Study Records Retention
Study documents will be retained for the longer of 3 years after close-out, 5 years after final reporting/publication, or 2 years after the last approval of a marketing application is approved for the drug for the indication for which it is being investigated or 2 years after the investigation is discontinued and FDA is notified if no application is to be filed or if the application has not been approved for such indication. No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained.

12.3 Protocol Deviations
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of Procedures (MOP) requirements. The noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by the site and implemented promptly.

It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report deviations.

Protocol deviations must be reported to the local IRB per their guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB requirements. Further details about the handling of protocol deviations will be included in the MOP.

12.4 Publication and Data Sharing Policy
This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication.

The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. The ICMJE policy, and the Section 801 of the Food and Drug Administration Amendments Act of 2007, requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library of Medicine. Other biomedical journals are considering adopting similar policies. For interventional clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee’s responsibility to register the trial in an acceptable registry, so the research results may be considered for publication in ICMJE member journals. The ICMJE does not review specific studies to determine whether registration is necessary; instead, the committee recommends that
researchers who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they wish to publish.

FDAAA mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register and report results of certain "applicable clinical trials":

- Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I investigations of a product subject to FDA regulation;
- Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation (other than small feasibility studies) and pediatric post-market surveillance studies.
- NIH grantees must take specific steps to ensure compliance with NIH implementation of FDAAA.

13. Study Finances

13.1 Funding Source
National Institutes of Health

13.2 Costs to the Participant
There will be no costs incurred related to the study medication, which will be provided by the study, or the baseline D-dimer blood test, which will be covered by the study. There will also be no costs related to participation in the optional biorepository. Participant health insurance may be billed for the costs of medical care during this study since these expenses would have happened even if you were not in the study, if their insurance does not cover these costs or participants do not have insurance, these costs will be participant responsibility.

14. Conflict of Interest Policy
The independence of this study from any actual or perceived influence, such as by the pharmaceutical industry, is critical. Therefore, any actual conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be required to have such conflicts managed in a way that is appropriate to their participation in the trial.

Any investigator who has a conflict of interest with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by the Conflict of Interest Management Unit (CIMU) with a Committee-sanctioned conflict management plan that has been reviewed and approved by the study sponsor prior to participation in this study. All investigators will follow the applicable conflict of interest policies.

15. References

References


Appendix 1: Criteria for Addition and Replacement of Arms

This master protocol trial design is built as a process, with the possibility of multiple interventions being investigated. In subsequent stages, this trial may incorporate 2 or more interventions, and the number of interventions may evolve as the science evolves and as data accrues during the course of the trial.
Appendix 2: Definition and Determination of Outcomes

A2.1 Approach to ascertainment and verification of outcomes

Patients will be enrolled and randomized in the inpatient setting, prior to discharge from the hospital (see Figure 1 in the main protocol). A total of six follow-up contacts would be made during the course of the study, at study days 2±1, 10±3, 20±3, 30±10, 45±14, and 90±14. Although one or more of these encounters may occur as part of an in-person study visit, we anticipate that most of these encounters will occur via remote telephone monitoring. All patient reported events will be investigated by the Central Coordinating Center, including obtaining information from healthcare facilities where patients received treatment and/or were admitted to the hospital. An independent central adjudication committee (ICAC) will review and adjudicate events in a blinded manner without awareness of treatment allocation. During the study period, the ICAC will adjudicate all suspected occurrences of venous or arterial thromboembolic events, acute myocardial infarction, acute ischemic stroke, and all-cause mortality. The ICAC will also review all reported episodes of bleeding and categorize these events as meeting criteria for major, non-major clinically relevant, or minor bleeding. The ICAC will also review all reported hospitalization events. The ICAC will be provided with all relevant documentation related to these events. The criteria and definitions of the study outcomes as well as the procedures followed by the Committee will be described in an adjudication manual which will be provided to the ICAC members prior to the first meeting.

A2.2 Outcome definitions

The primary study outcome is a composite endpoint of venous and/or arterial thromboembolic events, including new, symptomatic proximal or distal DVT of the upper or lower extremities, symptomatic PE, other venous thrombotic events, ischemic stroke, myocardial infarction, and mesenteric or peripheral arterial thromboses, and all-cause mortality up to 30 days after discharge from the hospital. These endpoints are individually defined below.

**Deep vein thrombosis**

Deep vein thrombosis will be diagnosed by venous ultrasound or point-of-care ultrasound (POCUS) or other imaging modality, performed for clinical indications and documented in a note. A positive ultrasound test is defined by a non-compressible or partially non-compressible venous segment in an upper or lower extremity. Deep vein thrombosis may be either proximal (e.g., femoral vein) or distal (e.g., deep veins of the calf), but thrombosis of a superficial vein only does not meet criteria for a DVT.

**Pulmonary embolism**

Pulmonary embolism will be confirmed by chest CT using a PE protocol (CTPA), ventilation-perfusion scan (V/Q), or digital subtraction angiography (DSA), performed for clinical indications. A positive CTPA is defined as a central contrast filling defect or complete occlusion up to the subsegmental level of the pulmonary arteries. A positive V/Q is defined as at least two large mismatched segmental perfusion defects or the arithmetic equivalent of moderate or large and moderate defects (revised PIOPED). A positive DSA is defined as a filling defect or a cut-off of a vessel of >2.5 mm. Source for criteria: [http://isth.breakthrough.healthcare/](http://isth.breakthrough.healthcare/).

**Other venous thrombotic events**

Other venous thrombotic events include cerebral sinus venous thrombosis, splanchnic venous thrombosis, or renal vein thrombosis, all confirmed by appropriate imaging studies (e.g., CT angiography, MR venography) performed for clinical indications.
Ischemic stroke
Ischemic stroke will be confirmed by head CT or MRI performed for the development of new symptoms (e.g., acute hemiplegia). A transient ischemic attack is not considered an outcome for this study.

Myocardial infarction
Myocardial infarction is defined according to the universal definition of MI, which excludes myocardial injury. MI must include rise and fall of cardiac troponin above the 99th percentile with ECG changes consistent with ischemia, plus: new/presumed new wall-motion abnormalities or other imaging evidence of MI; potentially ischemic symptoms; and/or abnormal coronary angiography.

Arterial thromboembolism
Arterial thromboembolism may involve a visceral organ (e.g., spleen, kidney) or limb and must be confirmed by appropriate imaging studies (e.g., CT angiography).

All-cause mortality
Death due to any cause.

Secondary study outcomes will include venous thromboembolism (inclusive of deep vein thrombosis, pulmonary embolism, and other venous thrombotic events) and arterial thromboembolism (inclusive of ischemic stroke, MI, and other arterial thromboembolic events) up to 30 days after discharge from the hospital, as well as the primary composite endpoint, up to 45 days and 90 days after discharge from the hospital.

Hospital re-admission
Re-admission to the hospital due to any cause.

Safety endpoints
Safety endpoints will include (1) major bleeding and (2) clinically-relevant non-major bleeding, both as defined by the International Society on Thrombosis and Haemostasis (ISTH).

Major bleeding
Bleeding events that are characterized as: (1) fatal bleeding; (2) bleeding into a critical area or organ (e.g., intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal); or (3) bleeding causing a fall in the hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells.

Clinically-relevant, non-major bleeding
Bleeding events that are characterized as: (1) bleeding requiring medical intervention by a healthcare professional; (2) bleeding leading to hospitalization or an increase in the level of care; or (3) bleeding prompting a face-to-face (i.e., not just a telephone or electronic communication) evaluation.
Appendix 3. Biospecimens

Biospecimens will be collected at two timepoints during the study, at the time of enrollment, and following completion of the antithrombotic therapy being studied (shortly after Day 30 for Stage 1). Samples that would be capable of participating in the biorepository would collect citrated plasma (2 tubes), serum, and a sample for genomic DNA.

At sites capable of sample collection and processing, additional samples may include: Pax gene DNA; Pax gene RNA; Platelets; and Cryopreserved PBMS.